Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

Detailed price information for Clearside Biomedi (CLSD-Q) from The Globe and Mail including charting and trades.

Opthea Limited’s OPT share price has dipped by 11.56%, which has investors questioning if this is right time to buy.

In this randomized controlled trial, cabozantinib significantly improved progression-free survival in patients with ...

KFDA approves Takedas Prucalopride capsules for metastatic colorectal cancer Approval granted for Takedas Prucalopride ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...

BACKGROUND: Lymphedema is an incurable disease associated with lymphatic dysfunction that causes tissue swelling and fibrosis ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

[143–145] The design of uniquely inhibitory peptide mimics that can block receptor–ligand interactions; [146–148] The size of the B-cell epitope should minimally be approximately 18 ...

One-hot encoding of receptor components revealed that VEGF MESA receptors containing a CD28 TMD in the C-terminal chain and a VEGFR1 ECD exhibited higher OS. The reduced categorical model ...